Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
The Long Run with Luke Timmerman
00:00
Lessons from growth and regulatory setbacks
Emily reflects on 23andMe's FDA conflict, regulatory lessons, and launching a therapeutics business.
Play episode from 25:20
Transcript
